Page 37 - Read Online

Rabadi et al. J Cancer Metastasis Treat 2022;8:24 https://dx.doi.org/10.20517/2394-4722.2022.06 Page 11 of 14

Financial support and sponsorship
Research was supported by NIH grants R01AR070760 and R01CA214062 (Randolph J. Noelle).

Conflicts of interest
Randolph J. Noelle is an inventor on patent applications (10035857, 9631018, 9217035, 8501915, 8465740,
8236304, and 8231872) submitted by Dartmouth College, and patent applications (9890215 and 9381244)
submitted by Kings College London and Dartmouth College and a co-founder of ImmuNext, a company
involved in the development of VISTA-related assets. These applications cover the use of VISTA targeting
for modulation of the immune response. Dina Rabadi is a past employee of ImmuNext.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Weir HK, Thompson TD, Stewart SL, White MC. Cancer incidence projections in the united states between 2015 and 2050. Prev
Chronic Dis 2021;18:E59. DOI PubMed PMC
2. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell
2017;168:707-23. DOI PubMed PMC
3. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350-5. DOI PubMed PMC
4. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 2018;8:1069-86.
DOI PubMed
5. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015;15:486-99. DOI PubMed
PMC
6. Thommen DS, Schreiner J, Müller P, et al. Progression of lung cancer is associated with increased dysfunction of t cells defined by
coexpression of multiple inhibitory receptors. Cancer Immunol Res 2015;3:1344-55. DOI PubMed
7. Xia A, Zhang Y, Xu J, Yin T, Lu XJ. T Cell dysfunction in cancer immunity and immunotherapy. Front Immunol 2019;10:1719.
DOI PubMed PMC
8. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced
melanoma. N Engl J Med 2017;377:1345-56. DOI PubMed PMC
9. Le Mercier I, Chen W, Lines JL, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res
2014;74:1933-44. DOI PubMed PMC
10. Kakavand H, Jackett LA, Menzies AM, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance
to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol 2017;30:1666-76. DOI PubMed
11. Gao J, Ward JF, Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients
with prostate cancer. Nat Med 2017;23:551-5. DOI PubMed PMC
12. Broughton TWK, ElTanbouly MA, Schaafsma E, et al. Defining the signature of VISTA on myeloid cell chemokine responsiveness.
Front Immunol 2019;10:2641. DOI PubMed PMC
13. Flies DB, Wang S, Xu H, Chen L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents
graft-versus-host disease in mouse models. J Immunol 2011;187:1537-41. DOI PubMed PMC
14. ElTanbouly MA, Zhao Y, Nowak E, et al. VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance.
Science 2020;367:eaay0524. DOI PubMed PMC
15. Wang L, Rubinstein R, Lines JL, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp
Med 2011;208:577-92. DOI PubMed PMC
16. Mehta N, Maddineni S, Mathews II, Sperberg AP, Huang PS, Cochran JR. Structure and functional binding epitope of v-domain Ig
suppressor of t-cell activation (VISTA). Cell Rep 2019;28:2509-16.e5. DOI
17. Slater BT, Han X, Chen L, Xiong Y. Structural insight into T cell coinhibition by PD-1H (VISTA). Proc Natl Acad Sci USA
2020;117:1648-57. DOI PubMed PMC
18. Yum JI, Hong YK. Terminating cancer by blocking VISTA as a novel immunotherapy: hasta la vista, baby. Front Oncol
2021;11:658488. DOI PubMed PMC